Moderna Awaits FDA Decision on mRNA-Based Flu Shot

Moderna is on the brink of learning whether their mRNA-based flu shot will receive approval from the Food and Drug Administration (FDA). This decision holds significant implications for mRNA technology’s future. Health Secretary Robert F. Kennedy Jr.’s skepticism about mRNA vaccine technology continues as the FDA reviews the shot.

The unfolding events began in February when Moderna received a surprise letter from the FDA. Stephen Hoge, Moderna’s president, described the tense moment as he learned of the FDA’s refusal to review their application. Though they had been in communication with the FDA throughout the process, the decision still came as a shock.

The FDA later reversed its decision, agreeing to a review after Moderna added a confirmatory study requirement.

In June, an advisory panel to the FDA recommended approving the vaccine. With a decision deadline approaching, the Moderna flu shot could become the first mRNA-based flu vaccine on the market. The FDA’s initial backtracking, however, sent ripples throughout the pharmaceutical industry. Consistency and fairness in regulatory actions are crucial for companies like Moderna, which rely on the U.S. market.

Rena Conti, a health economist at Boston University, highlighted the industry’s dependence on a predictable FDA. This uncertainty, coupled with the Department of Health and Human Services (HHS) retracting $500 million from mRNA research, raises concerns. An HHS spokesperson reiterated their commitment to maintaining public health standards without compromising innovation.

For smaller biotech firms, the situation is more precarious. Jeff Coller, a professor at Johns Hopkins University, pointed out the difficulty they face when a major player like Moderna encounters obstacles. This environment frightens venture capitalists who invest in small companies developing mRNA technologies for various conditions.

Janusz Racz represents many patients who benefit from mRNA innovations. He participated in a clinical trial for BioNTech’s mRNA cancer therapy after being diagnosed with Stage 3 lung cancer. Now cancer-free, Racz views mRNA therapies as a lifeline. However, he voiced his concern over the political climate that threatens future research, even writing a letter to Kennedy without receiving a response. He believes mRNA technology provides hope for countless individuals.